HII Successfully Completes Second Builder’s Sea Trials for Destroyer Ted Stevens (DDG 128)

(NYSE:HII), PASCAGOULA, Miss., Oct. 24, 2025 (GLOBE NEWSWIRE) — HII's (NYSE: HII) Ingalls Shipbuilding division successfully completed the second builder's sea trials for guided missile destroyer Ted Stevens (DDG 128), building on the success of the initial trials conducted at the end of September. The Arleigh Burke-class (DDG 51) destroyer spent multiple days in the […]

Compass Nova Scotia Expands Co-operative Housing Amid Housing Crisis Grand Opening of Unity North Neighbourhood Brings 57 New Co-op Homes to Halifax

Halifax, Nova Scotia, Oct. 24, 2025 (GLOBE NEWSWIRE) — As Nova Scotia faces a deepening housing crisis, the need for affordable, community-based solutions has never been greater. Today, Compass Nova Scotia Co-operative Homes (Compass NS), a growing co-operative housing organization dedicated to providing inclusive homes in resilient communities, proudly celebrates the grand opening of Unity

HII Successfully Completes Second Builder’s Sea Trials for Destroyer Ted Stevens (DDG 128)

HII Successfully Completes Second Builder's Sea Trials for Destroyer Ted Stevens (DDG 128) GlobeNewswire October 24, 2025 PASCAGOULA, Miss., Oct. 24, 2025 (GLOBE NEWSWIRE) — HII's (NYSE: HII) Ingalls Shipbuilding division successfully completed the second builder's sea trials for guided missile destroyer Ted Stevens (DDG 128), building on the success of the initial trials conducted

Compass Nova Scotia Expands Co-operative Housing Amid Housing Crisis Grand Opening of Unity North Neighbourhood Brings 57 New Co-op Homes to Halifax

Compass Nova Scotia Expands Co-operative Housing Amid Housing Crisis Grand Opening of Unity North Neighbourhood Brings 57 New Co-op Homes to Halifax GlobeNewswire October 24, 2025 Halifax, Nova Scotia, Oct. 24, 2025 (GLOBE NEWSWIRE) — As Nova Scotia faces a deepening housing crisis, the need for affordable, community-based solutions has never been greater. Today, Compass

Syndax Announces FDA Approval of Revuforj(R) (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia

(NASDAQ:SNDX), – First and only therapy FDA approved in both R/R acute myeloid leukemia (AML) with an NPM1 mutation and R/R acute leukemia with a KMT2A translocation – – Second approved indication for Revuforj in less than one year further solidifies Syndax's leadership in menin inhibition – – Included in NCCN Clinical Practice Guidelines in

Investors Urged to Contact Levi & Korsinsky for Information Before October 27, 2025 – LifeMD, Inc. (LFMD)

NEW YORK, NY / ACCESS Newswire / October 24, 2025 / If you suffered a loss on your LifeMD, Inc. (NASDAQ:LFMD) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/lifemd-inc-lawsuit-submission-form?prid=173888&wire=1&utm_campaign=5 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call

Syndax Announces FDA Approval of Revuforj(R) (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia

Syndax Announces FDA Approval of Revuforj(R) (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia GlobeNewswire October 24, 2025 – First and only therapy FDA approved in both R/R acute myeloid leukemia (AML) with an NPM1 mutation and R/R acute leukemia with a KMT2A translocation – – Second approved

COTHM Pakistan and MindHYVE.ai™ Forge Strategic Partnership to Pioneer AI-Powered Hospitality Education

The College of Tourism & Hotel Management (COTHM Pakistan) has signed a landmark Memorandum of Understanding (MoU) with MindHYVE.ai™, to usher in a new era of AI-powered learning and academic innovation in Pakistan's tourism and hospitality sector. https://mma.prnewswire.com/media/2804226/COTHM_Pakistan_x_MindHYVE.jpg The collaboration will see MindHYVE's ArthurAI™ adaptive learning platform deployed across COTHM's national network of campuses, transforming

Did You Lose Money on aTyr Pharma, Inc. (ATYR)? Levi & Korsinsky Urges Investors to Act Before December 8, 2025

NEW YORK, NY / ACCESS Newswire / October 24, 2025 / If you suffered a loss on your aTyr Pharma, Inc. (NASDAQ:ATYR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/atyr-pharma-inc-lawsuit-submission-form?prid=173886&wire=1&utm_campaign=28 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

WHEN HER MOTHER SAW, SHE WENT BLIND

Memoir from Child Abuse Advocate Hits USA Today Bestseller Andrea Leeb is a lawyer, a nurse, a scuba instructor, a yoga teacher, a bestselling author, a member of the advisory board of the UCLA Rape Treatment Center and Stuart House, and also the survivor of horrific childhood incest. https://mma.prnewswire.com/media/2804179/Andrea_Leeb___memoir.jpg Childhood sexual assault survivor & advocate's

Scroll to Top